Deutsche Bank AG Takes $3.56 Million Position in Intellia Therapeutics, Inc. $NTLA

Key Points

• Deutsche Bank acquired a new 210,550-share stake in Intellia Therapeutics during the second quarter, valued at approximately $3.56 million and representing about 0.15% of the company. Institutional investors collectively own 88.77% of NTLA.
• Intellia reported a quarterly loss of $0.80 per share, in line with estimates, but revenue of $7.66 million fell short of the $12.98 million consensus and declined 46.4% year over year. Analysts expect a full-year loss of approximately $3.21 per share.
• NTLA shares opened at $13.19, well below the average analyst target of $21.15; ratings remain mixed, resulting in a consensus “Hold.” The company’s CRISPR/Cas9 pipeline focuses on potential gene-editing treatments for transthyretin amyloidosis and other genetic diseases.

Deutsche Bank AG bought a new position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 210,550 shares of the company's stock, valued at approximately $3,563,000. Deutsche Bank AG owned about 0.15% of Intellia Therapeutics as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Oppenheimer & Co. Inc. increased its position in Intellia Therapeutics by 0.8% in the fourth quarter. Oppenheimer & Co. Inc. now owns 105,165 shares of the company's stock worth $945,000 after purchasing an additional 808 shares during the period. Comerica Bank lifted its position in Intellia Therapeutics by 45.8% during the 4th quarter. Comerica Bank now owns 2,869 shares of the company's stock valued at $26,000 after purchasing an additional 901 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of Intellia Therapeutics by 36.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,552 shares of the company's stock valued at $46,000 after purchasing an additional 948 shares during the last quarter. Wealthfront Advisers LLC boosted its stake in shares of Intellia Therapeutics by 7.6% in the 1st quarter. Wealthfront Advisers LLC now owns 14,450 shares of the company's stock valued at $185,000 after purchasing an additional 1,018 shares during the last quarter. Finally, Benjamin Edwards Inc. grew its position in shares of Intellia Therapeutics by 1.8% during the 2nd quarter. Benjamin Edwards Inc. now owns 63,034 shares of the company's stock worth $591,000 after buying an additional 1,126 shares during the period. Institutional investors and hedge funds own 88.77% of the company's stock.

Intellia Therapeutics Price Performance

Intellia Therapeutics stock opened at $13.19 on Thursday. The firm has a market capitalization of $1.85 billion, a price-to-earnings ratio of -3.93 and a beta of 1.81. The company's 50 day simple moving average is $13.36 and its 200 day simple moving average is $13.37. Intellia Therapeutics, Inc. has a fifty-two week low of $7.95 and a fifty-two week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, meeting the consensus estimate of ($0.80). The firm had revenue of $7.66 million during the quarter, compared to the consensus estimate of $12.98 million. Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 57.79%. The business's quarterly revenue was down 46.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.98) earnings per share. As a group, analysts predict that Intellia Therapeutics, Inc. will post -3.21 EPS for the current fiscal year.

Insiders Place Their Bets

In other Intellia Therapeutics news, EVP Edward J. Dulac III sold 4,677 shares of the business's stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total value of $84,186.00. Following the completion of the transaction, the executive vice president directly owned 156,286 shares of the company's stock, valued at approximately $2,813,148. The trade was a 2.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Michael P. Dube sold 2,641 shares of the business's stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $16.78, for a total value of $44,315.98. Following the completion of the transaction, the chief accounting officer directly owned 66,886 shares of the company's stock, valued at approximately $1,122,347.08. The trade was a 3.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

NTLA has been the topic of several analyst reports. Wall Street Zen lowered shares of Intellia Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday, August 8th. HC Wainwright reaffirmed a "buy" rating and set a $25.00 target price on shares of Intellia Therapeutics in a report on Monday, June 15th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Intellia Therapeutics in a research report on Friday, July 17th. Wedbush increased their price target on Intellia Therapeutics from $12.00 to $17.00 and gave the company a "neutral" rating in a research note on Friday, July 10th. Finally, New Street Research set a $25.00 price target on Intellia Therapeutics in a research report on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, eight have assigned a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $21.15.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc NASDAQ: NTLA is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company's research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia's lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source